Table 2.

Clinical characteristics of patients with serum HBsAg loss during PD-1 inhibitor combinational therapy.

Patient	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7
Age	61	48	57	70	62	50	52
Gender (male, female)	male	male	male	male	male	male	male
Cancer type	Liver cancer	Gastric cancer	Liver cancer	Liver cancer	Gastric cancer	Liver cancer	Liver cancer
Liver cirrhosis (yes/no)	Yes	No	Yes	Yes	Yes	Yes	Yes
HBeAg status (seronegative/seropositive)	Seronegative	Seronegative	Seronegative	Seronegative	Seronegative	Seronegative	Seronegative
Baseline HBsAg (IU/ml)	0.19	0.25	57.20	1.14	0.35	0.77	1.97
Baseline HBV-DNA (IU/ml)	Not detected	<100	<20	<100	<100	<20	<100
Prior use of antiviral therapy (yes/no)	Yes	No	Yes	Yes	Yes	Yes	Yes
Cycles of PD-1 inhibitor	9	5	11	14	4	2	2
Weeks to achieve HBsAg loss (since PD-1 inhibitor initiation)	26.00	18.86	27.71	42.86	11.43	12.14	9.29
PD-1 inhibitor type	Tislelizumab	Sintilimab	Camrelizumab	Sintilimab	Sintilimab	Tislelizumab Sintilimab	Sintilimab
Antiviral treatment regimen	ETV	ETV	TDF	TAF	TDF	ETV	TDF, TAF
Combined therapy	Lenvatinib	Chemotherapy	Apatinib Oncolytic virotherapy	Donafenib	Chemotherapy	Donafenib TACE	Chemotherapy Lenvatinib
HBV reactivation (yes/no)	No	No	No	No	No	No	No
HBsAg seroconversion (yes/no)	No	No	Yes	No	No	No	No

HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; PD-1, programmed cell death protein-1; TACE, transcatheter arterial chemoembolization; ETV, Entecavir; TDF, Tenofovir disoprox fumarate; HBsAg seroconversion, defined as anti-HBs changing from negative at baseline to positive at any postbaseline visit with HBsAg loss occurring within the targeted time window.